Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. (Q38199533)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24669979%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24669979%20AND%20SRC:MED&resulttype=core&format=json

chronic obstructive pulmonary disease

12 March 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24669979%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Maria Gabriella Matera

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24669979%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Mario Cazzola

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24669979%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

English

0 references

publication date

26 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24669979%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24669979%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24669979%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24669979%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

961-977

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24669979%20AND%20SRC:MED&resulttype=core&format=json

Pharmacology and therapeutics of bronchodilators

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Novel bronchodilators for the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

An update on bronchodilators in Phase I and II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Long-acting muscarinic receptor antagonists for the treatment of respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Aclidinium bromide for the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Alternative mechanisms for tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Tiotropium bromide inhibits TGF-&szlig;-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Aclidinium inhibits human lung fibroblast to myofibroblast transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

21 January 2018

Mucus and MUC in asthma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Effect of ipratropium bromide on airway mucociliary function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Chronic persistent cough: use of ipratropium bromide in undiagnosed cases following upper respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

The effect of anticholinergic bronchodilator therapy on cough during upper respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Effect of tiotropium on cough reflex sensitivity in acute viral cough

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

The cardiovascular risk of tiotropium: is it real?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Tiotropium Respimat inhaler and the risk of death in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Cardiovascular safety of tiotropium in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Tiotropium Respimat increases the risk of mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Triple therapy for the management of COPD: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

The MABA approach: a new option to improve bronchodilator therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Olodaterol: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Chronic obstructive pulmonary disease exacerbations: accurate and easy measurement promises much

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and β2 agonists in combination or combined into a single molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Multivalent dual pharmacology muscarinic antagonist and β₂ agonist (MABA) molecules for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

A new class of bronchodilator improves lung function in COPD: a trial with GSK961081.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Ba 679 BR, a novel long-acting anticholinergic bronchodilator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Long‐lasting target binding and rebinding as mechanisms to prolong in vivo drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Symptom variability in patients with severe COPD: a pan-European cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

In vitro anticholinergic drugs affect CD8+ peripheral blood T-cells apoptosis in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.899581

10.1517/14656566.2014.899581

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24669979%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference